New treatment tested for severe Muscle-Weakening disease
NCT ID NCT07413835
Summary
This study is testing an investigational treatment called HN2302 in a small group of adults with myasthenia gravis that hasn't responded well to standard therapies. The main goal is to see if HN2302 is safe and tolerable, while also checking for early signs that it might help improve patients' daily activities, muscle strength, and quality of life. Researchers will monitor participants for a year to track their health and any changes in their condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, 221000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.